WinstonWınston
Futura Medical logo

Futura Medical

FUM.L
41
Biotechnology · Healthcare
Price
0.36 GBp
+0.04 (+14.52%)
Market Cap
1.2M GBp
Exchange
London Stock Exchange
Winston Score
41
Winston is serious
Mixed quality — meaningful strengths and weaknesses.

Share count rising — dilution

+20.3% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 271.0M (2021) → 326.0M (2025)

Futura Medical is a small UK-based biotechnology company focused on developing medicines that are applied directly to the skin, known as transdermal drug delivery. Its main product is Eroxon, a gel treatment for erectile dysfunction that works quickly and is available without a prescription. The company sells to consumer healthcare markets, primarily targeting adults who want an over-the-counter alternative to prescription pills.

Futura makes money by licensing its products and technology to larger pharmaceutical and consumer health companies, who then handle manufacturing and distribution. Eroxon has received regulatory approval in the US, UK, and parts of Europe, giving Futura a foothold in a large global market. However, the company is still in an early commercial stage, spends far more than it earns, and depends heavily on its partners successfully marketing Eroxon at scale — meaning slow consumer adoption or weak partner execution remains the central risk to its future growth.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-90.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-530.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$2M/ year

Declining (-7% vs prior year)

95.1% of revenue

5.3x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

9.2%ownership

Insiders own a meaningful stake in the company

Cash Runway

~4 months

$3M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Cash watch

Futura Medical has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
143.3%
Premium pricing power — 143.3% gross margin
Operating Margin
153.3%
Excellent — 153.3% operating margin
ROCE
38.0%
Exceptional — 38.0% return on capital

ROIC above 25%. Every dollar invested in the business earns more than 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-87.8%
Shrinking sales (-87.8% YoY)
EPS YoY
-704.7%
Earnings shrinking (-704.7% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency
0/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-328.7%
Burning cash (-328.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
N/A
Data not available
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial